U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07305974) titled 'A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy' on Dec. 07.
Brief Summary: This study looks at how well and safely RG002C0106 works for patients with certain kidney disease: primary IgA nephropathy. It's a phase IIa trial done at several locations where both patients and doctors unknow what treatment is being given.
Study Start Date: Sept. 08
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy (IgAN)
Intervention:
DRUG: RG002C0106
RG002C0106 for subcutaneous (SC) injection
DRUG: placebo subcutaneous administration
The placebo is made of normal saline.
Recruitment Status: RECRU...